Chronic Dorzagliatin on Insulin and Incretin Function in Intermediate Hyperglycemia and Type 2 Diabetes
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorElaine Chow
About this trial
A total of 30 subjects will be recruited 15 with intermediate hyperglycemia and 15 in the tyep 2 diabetes group respectively. Eligible participants will undergo hyperglycemic-clamp/oral glucose tolerance at baseline and after 4 weeks of dorzagliatin treatment.
Eligibility criteria
Qualifiers
Individuals aged ≥ 18 years but < 70 years
Male or female
Body mass index of over 18 kg/m2 and < 35 kg/m2
Fasting plasma glucose <7.0 mmol/L and HbA1c < 6.5%
Disqualifiers
1. Subjects who do not agree to participate in this study. 2. Country of birth is unknown. 3. Body weight less than 45kg. 4. Acute phase of cerebrovascular and cardiovascular diseases (within 6 months of recruitment).
Trial design
Treatments tested in this trial
- Dorzagliatin
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Elaine Chow
Lead sponsor
Chinese University of Hong Kong
Sponsor institution
Source ClinicalTrials.gov